General Updates

October 8, 2026 BSE Limited The National Stock Exchange of India Limited Floor 25, P. J. Towers Exchange Plaza Dalal Street, Bandra Kurla Complex, Bandra (E) Mumbai - 400 001 Mumbai - 400 051 Scrip Code: 530019 Symbol: JUBLPHARMA Subject: Intimation under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 Dear Sir, Madam, We wish to inform you that Jubilant’s Radiopharma business announces investment of CAD 94.5 million to double production capacity of its flagship product, RUBY-FILL®. Date and Time – October 8, 2026; 08:00 PM (IST) The above mentioned document will be simultaneously posted on the Company's website at www.jubilantpharmova.com. We request you to take the same on record. Thanking you, Yours faithfully, For Jubilant Pharmova Limited Naresh Kapoor Company Secretary Encl: As above Jubilant Pharmova Limited 1A, Sector 16A, Noida – 201301, India Tel.: +91 120 4361000 www.jubilantpharmova.com PRESS RELEASE Noida, October 8, 2026 Jubilant’s Radiopharma business announces investment of CAD 94.5 million to double production capacity of its flagship product, RUBY-FILL® The Government of Canada will provide a financial support of CAD 23.8 million to this project through the Strategic Response Fund’s innovation funding stream. Jubilant Draximage Inc., a subsidiary of company’s wholly owned subsidiary Jubilant Pharma Limited, today announced an investment of CAD 94.5 million to modernize and expand its Kirkland, Québec facility and increase production capacity across its radiopharmaceutical portfolio pipeline. Specifically, the investment is aimed to double the production capacity of its flagship product RUBY-FILL®. The Government of Canada will provide a financial support of CAD 23.8 million to this project. The business continues to see very strong demand for the RUBY-FILL®, the customer base has doubled in the last 3 years. This expansion will allow Jubilant to fulfil the elevated demand. Speaking on the announcement, Harsher Singh, CEO, Jubilant Radiopharma business said, “This investment recognizes Jubilant Radiopharma’s innovation capabilities in Nuclear Medicine and the important role our sector plays in advancing both diagnostic and therapeutic treatments. This project will build our deep capability here in Quebec, create and secure high-value jobs, and ensure a reliable supply of essential radiopharmaceutical products in Canada and around the world. ” Jubilant Radiopharma’s portfolio spans both diagnostic and therapeutic solutions that support precision medicine across cardiology, oncology, and nuclear medicine. Specifically, RUBY-FILL® enables the on-site production of Rubidium-82 for cardiac PET imaging, helping clinicians accurately assess coronary artery disease and improve patient care. The Technetium-99m (99mTc) diagnostic portfolio supports a broad range of SPECT imaging procedures. These products play a critical role in disease detection, diagnosis, staging, and treatment planning across multiple clinical specialties, including oncology, cardiology, and neurology. In the therapeutic space, our Iodine-131 products have long supported the treatment of thyroid disease, thyroid cancer and neuroblastoma through targeted delivery of radiation to diseased tissue. The Kirkland facility is the only site in Canada producing these product categories. The investment will support the modernization and expansion of the facility, including the installation of state-of-the-art production equipment, enabling Jubilant Radiopharma to double its manufacturing capacity to meet growing global demand for RUBY- FILL®. About Jubilant Radiopharma Jubilant Radiopharma is an industry-leading radiopharmaceutical business that comprises development, manufacturing and commercialization of products through its Radiopharmaceuticals business and distribution through its national network of Radiopharmacies. The division’s Radiopharmacies business is the second largest radiopharmacy network in the US with 45 pharmacies distributing nuclear medicine products to the largest national Group Purchasing Organisations (GPOs), regional health systems, stand-alone imaging centres, cardiologists and hospitals. Jubilant Radiopharma is focused on “Improving Lives through Nuclear Medicine” on a global scale. About Jubilant Pharmova Limited Jubilant Pharmova Limited is an integrated global pharmaceutical company engaged in Radiopharma, Allergy Immunotherapy, Contract Development and Manufacturing of sterile injectable, Contract Research Development and Manufacturing, Generics and Proprietary Novel Drugs businesses. With a network of 45 radiopharmacies in the USA, the Radiopharma business is engaged in manufacturing and supply of radiopharmaceutical products and services. The Allergy Immunotherapy business is involved in the manufacturing and supply of allergic extracts and venom products in the USA and other markets such as Canada, Europe and Australia. Contract Development and Manufacturing of sterile injectables, with facilities in Spokane, USA, and Montreal, Canada, delivers end-to-end manufacturing solutions, including sterile fill-and-finish injectables (liquid and lyophilized), comprehensive ophthalmic products (liquids, ointments and creams) and ampoules. Contract Research Development and Manufacturing business provides end-to- end drug discovery and development services to the pharmaceutical and biotech industries through three world class research centres (two in India and one in France) and a US FDA approved, Active Pharmaceutical Ingredients manufacturing facility in Nanjangud, Karnataka. The Generics business focuses on development, manufacturing and distribution of Solid Dosage Formulations through multiple manufacturing facilities that cater to all the regulated market including USA, Europe and other geographies. Proprietary Novel Drugs is an innovative biopharmaceutical business developing breakthrough therapies in the area of oncology and auto-immune disorders. Jubilant Pharmova has a team of around 5,500 multicultural people across the globe. The Company is well recognised as a ‘Partner of Choice’ by leading pharmaceuticals companies globally. For more information, please visit: www.jubilantpharmova.com For more information, please contact: For Investors Runjhun Jain Pankaj Dhawan EY India Phone: +91 120 436 1105 Phone: +91 98207 20993 E-mail: Pankaj.dhawan@jubl.com E-mail: runjhun.jain1@in.ey.com For Media Jyoti Sharma Sandipan Ghatak Ad Factors PR Phone: +91-98107 76182 Phone: +91 9810519900 E-mail: sandipan.ghatak@jubl.com E-mail: jyoti.sharma@adfactorspr.com Disclaimer Statements in this document relating to future status, events, or circumstances, including but not limited to statements about plans and objectives, the progress and results of research and development, potential product characteristics and uses, product sales potential and target dates for product launch are forward-looking statements based on estimates and the anticipated effects of future events on current and developing circumstances. Such statements are subject to numerous risks and uncertainties and are not necessarily predictive of future results. Actual results may differ materially from those anticipated in the forward-looking statements. Jubilant Pharmova may, from time to time, make additional written and oral forward-looking statements, including statements contained in the company’s filings with the regulatory bodies and its reports to shareholders. The company assumes no obligation to update forward-looking statements to reflect actual results, changed assumptions or other factors.